|
|
|
| Economic evaluation on new strategy for preventing poliomyelitis in Zhejiang Province |
| TANG Xue-wen,ZHOU Yang,DENG Xuan,YAN Rui,XIE Shu-yun,HE Han-qing
|
| Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou,Zhejiang,310051,China |
|
|
|
|
Abstract Objective To evaluate the economic effect of new strategy for preventing poliomyelitis in Zhejiang Province. Methods Based on the population of Zhejiang Province in 2016,cost-effectiveness ratio（CER）,benefit-cost ratio（BCR）,and net benefit（NB）were applied to calculate the health economic difference for the new strategy and the original strategy as compared to no vaccination strategy. Univariate sensitivity analysis was used to assess the robustness of results with main parameters; including burdens of poliomyelitis,cost of vaccines,and the vaccination program itself,and the discount rate. Results CERdisease,CERdeath,BCR and NB for the new strategy were 1:52700 RMB Yuan per case,1:1813700 RMB Yuan per case,12.26 and 796.6622 million and CERdisease,CERdeath,BCR and NB for the original strategy were 1:32900 RMB Yuan per case,1:1133900 RMB Yuan per case,19.58 and 823.1753 million,respectively. The results of the univariate sensitivity analysis with main parameters were robust. Conclusion The new strategy for preventing poliomyelitis is necessary for this period of the global polio eradication. Though the new strategy appears not as good as the original strategy on economic evaluation,its health economic benefit is significant.
|
|
Published: 07 December 2017
|
|
|
|
|
|
[1] WHO.Polio Vaccines:WHO Position Paper,January 2014[Z]. WER,2014,89（9）:73-92.
[2] Global Poliomyelitis Eradication Initiative.Poliomyelitis eradication and endgame strategic plan,2013—2018[EB/OL]. http:// www.poliomyelitis eradication.org/Portals/0/Document/Resour- Ces/ Straregy Work/EndgameStratPlan-20130409_ENG.pdf.
[3] DUINTJER,TEBBENS R J,THOMPSON K M.The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management[J]. Future Microbiol,2016（11）:1549-1561.
[4] WHO. 全球消灭脊髓灰质炎前的脊髓灰质炎疫苗及其免疫接种:WHO立场文件[Z]. 2010.
[5] WHO.Polio Vaccines:WHO position paper-March,2016[Z]. WER,2016,91（ 12 ）:145-168.
[6] ARITA M. Poliovirus Studies during the Endgame of the Polio Eradication Program[J]. Jpn J Infect Dis,2017,70（1）:1-6.
[7] KHAN M T,ZAHEER S,SHAFIQUE K. Maternal education,empowerment,economic status and child polio vaccination uptake in Pakistan:a population based cross sectional study[J]. BMJ Open,2017,7（3）:e013853.
[8] LI R C,LI C G,WANG H B,et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China[J]. J Pediatric Infect Dis Soc,2016,5（3）:287-296.
[9] 何寒青,陈恩富,李倩,等. 浙江省1978—2007年计划免疫卫生经济学评价[J]. 中国农村卫生事业管理,2010,30（10）:835-837.
[10]World Health Organization.WHO guide for standardization of economic evaluations of immunization program[M]. Geneva:WHO Document Production Services,2008:56-57.
[11]ZHOU F,ORTEGA-SANCHEZ I R,GURIS D,et al. An economic analysis of the universal varicella vaccination program in the United States[J]. J Infect Dis,2008,197（Suppl 2）:S156-S164.
[12]何寒青,张兵,严睿,等. 不同免疫程序接种2剂麻疹-流行性腮腺炎-风疹联合减毒活疫苗的卫生经济学评价[J]. 中华流行病学杂志,2016,37（8）:1121-1126.
[13]孙烨祥,林鸿波,李珊燕. 首剂IPV纳入免疫规划前儿童脊髓灰质炎疫苗接种情况分析[J]. 预防医学,2017,29（4）:368-371.
[14]刘白羽,刘勇,王少华. 山东省脊髓灰质炎计划免疫的社会效果与经济效益[J]. 中国公共卫生管理杂志,1991（S1）:287. |
|
|
|
